Skip to main content
Top
Published in: Annals of Surgical Oncology 3/2009

01-03-2009 | Thoracic Oncology

Bedside Talc Pleurodesis for Malignant Pleural Effusion: Factors Affecting Success

Authors: Umit Aydogmus, MD, Servet Ozdemir, MD, Levent Cansever, MD, Yasar Sonmezoglu, MD, Celalettin Ibrahim Kocaturk, MD, Mehmet Ali Bedirhan, MD

Published in: Annals of Surgical Oncology | Issue 3/2009

Login to get access

Abstract

Introduction

To determine the factors affecting the success of bedside talc slurry (TS) used for symptomatic treatment of patients with malignant pleural effusion (MPE).

Methods

Data of 113 effusions in 103 MPE patients treated between 1999 and 2007 were retrospectively evaluated for the study. The study group involved 73 patients whose follow-up information was available out of 81 patients treated by TS. Causes of MPE were lung cancer in 22 patients (30.1%) and breast carcinoma in 21 patients (28.8%).

Results

The success rate of TS was significantly higher if the time period between radiological diagnosis of effusion and administration of TS was less than 30 days (P = .02), or spontaneous expansion was attained after chest tube drainage (CTD) (P = .01). Success rate was higher for patients with daily drainage of less than 200 ml before TS than patients with more than 200 ml of daily drainage (P = .01). Dose of talc, either 4 g or above (P = .34), primary cause of MPE (P = .53), time to termination of CTD (P = .57), amount of drainage when CTD was terminated (P = .23), and time period between CTD and administration of TS (P = .20) did not show a statistically significant effect on the success of TS.

Conclusion

In the treatment of malignant pleural effusion, patients with daily drainage of less than 200 ml before TS developed less recurrence than patients with daily drainage of more than 200 ml. Longer time period between the diagnosis of MPE and onset of CTD increased recurrence.
Literature
1.
go back to reference Tremblay A, Michaud G. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest. 2006;129:362–8.PubMedCrossRef Tremblay A, Michaud G. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest. 2006;129:362–8.PubMedCrossRef
2.
go back to reference Antunes G, Neville E, Duffy J, et al. BTS guidelines for the management of malignant pleural effusions. Thorax. 2003;58(Suppl II):ii29–38.PubMed Antunes G, Neville E, Duffy J, et al. BTS guidelines for the management of malignant pleural effusions. Thorax. 2003;58(Suppl II):ii29–38.PubMed
3.
go back to reference Tan C, Sedrakyan A, Browne J, et al. The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. Eur J Cardiothorac Surg. 2006;29:829–38.PubMedCrossRef Tan C, Sedrakyan A, Browne J, et al. The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. Eur J Cardiothorac Surg. 2006;29:829–38.PubMedCrossRef
4.
go back to reference Kuzniar TJ, Blum MG, Kasibowska-Kuzniar K, et al. Predictors of acute lung injury and severe hypoxemia in patients undergoing operative talc pleurodesis. Ann Thorac Surg. 2006;82:1976–81.PubMedCrossRef Kuzniar TJ, Blum MG, Kasibowska-Kuzniar K, et al. Predictors of acute lung injury and severe hypoxemia in patients undergoing operative talc pleurodesis. Ann Thorac Surg. 2006;82:1976–81.PubMedCrossRef
5.
go back to reference Cohen RG, Shely WW, Thompson SE, et al. Talc pleurodesis: Talc slurry versus thoracoscopic talc insufflation in a porcine model. Ann Thorac Surg. 1996;62:1000–2.PubMedCrossRef Cohen RG, Shely WW, Thompson SE, et al. Talc pleurodesis: Talc slurry versus thoracoscopic talc insufflation in a porcine model. Ann Thorac Surg. 1996;62:1000–2.PubMedCrossRef
6.
go back to reference Shan SA. Malignant pleural effusions. In: Shields TW, editors. General Thoracic Surgery. 6th ed., vol. 1. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 935–43. Shan SA. Malignant pleural effusions. In: Shields TW, editors. General Thoracic Surgery. 6th ed., vol. 1. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 935–43.
7.
go back to reference Haas RA, Sterman DH, Musani AI. Malignant pleural effusions management options with consideration of coding, billing, and a decision approach. Chest. 2007;132:1036–41.PubMedCrossRef Haas RA, Sterman DH, Musani AI. Malignant pleural effusions management options with consideration of coding, billing, and a decision approach. Chest. 2007;132:1036–41.PubMedCrossRef
8.
go back to reference Ong KC, Indumathi V, Raghuram J, et al. A comparative study of pleurodesis using talc slurry and bleomycin in the management of malignant pleural effusions. Respirology. 2000;5:99–103.PubMedCrossRef Ong KC, Indumathi V, Raghuram J, et al. A comparative study of pleurodesis using talc slurry and bleomycin in the management of malignant pleural effusions. Respirology. 2000;5:99–103.PubMedCrossRef
9.
go back to reference Dresler CM, Olak J, Herndon II JE, et al. Phase III intergroup study of talc poudrage versus talc slurry sclerosis for malignant pleural effusions. Chest. 2005;127:909–15.PubMedCrossRef Dresler CM, Olak J, Herndon II JE, et al. Phase III intergroup study of talc poudrage versus talc slurry sclerosis for malignant pleural effusions. Chest. 2005;127:909–15.PubMedCrossRef
10.
go back to reference DeCampos JR, Vargas FS, DeCampos Werebe E, et al. Thoracoscopy talc poudrage: a 15-year experience. Chest. 2001;119:801–6.CrossRef DeCampos JR, Vargas FS, DeCampos Werebe E, et al. Thoracoscopy talc poudrage: a 15-year experience. Chest. 2001;119:801–6.CrossRef
11.
12.
go back to reference Stefani A, Natali P, Casali C, et al. Talc poudrage versus talc slurry in the treatment of malignant pleural effusion: a prospective comparative study. Eur J Cardiothorac Surg. 2006;30:827–32.PubMedCrossRef Stefani A, Natali P, Casali C, et al. Talc poudrage versus talc slurry in the treatment of malignant pleural effusion: a prospective comparative study. Eur J Cardiothorac Surg. 2006;30:827–32.PubMedCrossRef
13.
go back to reference Burrows CM, Mathews WC, Colt HG. Predicting survival in patients with recurrent symptomatic malignant pleural effusion: an assessment of the prognostic values of physiologic, morphologic and quality of life measures of extent of disease. Chest. 2000;117:73–8.PubMedCrossRef Burrows CM, Mathews WC, Colt HG. Predicting survival in patients with recurrent symptomatic malignant pleural effusion: an assessment of the prognostic values of physiologic, morphologic and quality of life measures of extent of disease. Chest. 2000;117:73–8.PubMedCrossRef
14.
go back to reference Kolschmann S, Ballin A, Gillissen A. Clinical efficacy and safety of thoracoscopic talc pleurodesis in malignant pleural effusions. Chest. 2005;128:1431–5.PubMedCrossRef Kolschmann S, Ballin A, Gillissen A. Clinical efficacy and safety of thoracoscopic talc pleurodesis in malignant pleural effusions. Chest. 2005;128:1431–5.PubMedCrossRef
15.
go back to reference Warren WH, Kim AW, Liptay MJ. Identification of clinical factors predicting Pleurx® catheter removal in patients treated for malignant pleural effusion. Eur J Cardiothorac Surg. 2008;33:89–94.PubMedCrossRef Warren WH, Kim AW, Liptay MJ. Identification of clinical factors predicting Pleurx® catheter removal in patients treated for malignant pleural effusion. Eur J Cardiothorac Surg. 2008;33:89–94.PubMedCrossRef
Metadata
Title
Bedside Talc Pleurodesis for Malignant Pleural Effusion: Factors Affecting Success
Authors
Umit Aydogmus, MD
Servet Ozdemir, MD
Levent Cansever, MD
Yasar Sonmezoglu, MD
Celalettin Ibrahim Kocaturk, MD
Mehmet Ali Bedirhan, MD
Publication date
01-03-2009
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 3/2009
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-008-0263-x

Other articles of this Issue 3/2009

Annals of Surgical Oncology 3/2009 Go to the issue